INTRODUCTION
Great advances have been made since the ®rst therapeutically successful dialysis was described in 1943. 1 Dialysis was at ®rst a prolonged, expensive and labour-intensive procedure which was only used to prevent death from hyperkalaemia or¯uid overload, being limited to young patients with acute renal failure while their own kidneys recovered. Later, this indication was extended to patients destined for urgent renal transplantation.
With advances in technology, dialysis has now become cheaper and less onerous: more than 95% of the dialyses performed in the UK are for chronic renal failure on a routine outpatient basis; only 25% of patients on dialysis are waiting for a transplant. 2 As there is a shortage of cadaveric donors only one-third of those on the list will receive a kidney transplant. This means that the majority of such patients will spend the rest of their lives on dialysis. It is therefore no longer suf®cient to keep the electrolytes within safe levels and the patient out of pulmonary oedema. The aim must be to keep the patients healthy and mobile, and so prolong their survival. Thus the concept of dialysis adequacy has developed over the last 20 years.
POTENTIAL MARKERS FOR DIALYSIS ADEQUACY
No one molecule accounts for all the manifestations of renal failure. The kidney eliminates many different molecules, some of which have been implicated as uraemic toxins. These include urea, creatinine, potassium, hydrogen and phosphate ions, as well as a group of poorly de®ned solutes of molecular weight between 500 and 5000 kDa, known collectively as`middle molecules'. 3, 4 These have been shown to cause neurotoxicity, but correlate poorly with other uraemic symptoms. A much larger molecule, b 2microglobulin, accumulates in renal failure. It is deposited as amyloid, but only causes symptoms after 5±10 years on dialysis. Guanidines, phenols and indoles, 5 as well as hormones, especially parathyroid hormone, 6 have also been put forward as`toxins'.
These molecules come in a wide range of sizes, lipid solubilities and protein binding, and are therefore transferred across the dialysis membrane at different rates. It would take an ambitious, complex mathematical model to account for all of them. Ideally a single marker is needed. Such a marker should be easy and cheap to measure, its blood concentrations should correlate with symptoms, it should be retained in parallel with other signi®cant toxins, and the extent of its removal with dialysis should correlate with improvement in the patient's morbidity and mortality.
UREA AS A MARKER OF DIALYSIS ADEQUACY
Urea has a number of properties which make it the most attractive of all the potential markers. First, it is cheap and simple to measure. Second, serum urea concentration correlates well with symptoms and signs of renal failure. 7 It remains uncertain whether urea itself is toxic or simply a marker for the accumulation of other, less easily measured toxins. 8 Investigators who dialysed patients against a high urea concentration 9,10 saw no symptoms with serum urea concentrations up to 120 mmol/L, and only headache, nausea and decreased platelet function with those of 240 mmol/L. The symptoms were worse when serum urea concentrations were increased quickly, which suggests that they were caused by the osmotic change. However, these studies examined only the acute toxicity of urea; isocyanate derived from urea has been shown to cause non-enzymatic carbamylation of protein, notably haemoglobin, 11, 12 and chronic uraemia could be harmful. Horkko et al. 13 have shown that low-density lipoprotein is poorly cleared from the plasma when carbamylated, and could be implicated in the vascular disease of chronic renal failure.
Urea is unique among the possible markers in providing additional, crucial information regarding a patient's nitrogen balance. Being the end-product of protein breakdown, urea concentration is directly related to the protein catabolic rate (PCR): blood urea concentrations re¯ect the balance between protein catabolism and clearance. It is important to realize that good' ± i.e. low ± pre-dialysis urea concentrations may re¯ect poor protein intake just as well as adequate dialytic clearance. Consequently, to assess the dialysis process accurately, modelling of urea kinetics is required that simulates the movement of urea to, from and within the body during and between dialyses. The main proponents of urea kinetic modelling have been Sargent and Gotch. 14 It has become accepted as the best method of assessing and monitoring dialysis adequacy ever since it was used to design and control the landmark experimental dialysis study, the National Cooperative Dialysis Study (NCDS). 15 
NATIONAL COOPERATIVE DIALYSIS STUDY
The NCDS was published in 1981 and was the ®rst and largest prospective study to show a correlation between the amount of haemodialysis prescribed and morbidity. 15 A total of 160 patients from nine American centres were prospectively randomized into one of four treatment groups. The groups were based on combinations of low and high time-averaged urea concentration (TAC urea ), and short and long dialysis time (see Table 1 ). The timeaveraged concentration is the mean blood urea during a full dialysis cycle, in this case a thriceweekly schedule. Target dialysis time was either 4´5 h or 3 h, and target TAC urea was 40 or 20 mmol/L. Protein intake was prescribed at between 0´8 and 1´4 g/kg/day. The TAC urea was achieved by altering dialysis parameters and not through dietary manipulation. The patients were studied for a minimum of 6 months and a maximum of 3 years.
Patients were withdrawn from the study in the event of death, transplantation, patient choice or medical complications, such as anorexia, nausea, pericarditis, myocardial infarction or gastrointestinal bleeding.
The two regimens with the higher TAC urea (groups II and IV) were associated with increased morbidity. Patients in group IV (high TAC urea , short dialysis time) were withdrawn 9 months before the end of the trial, when it became obvious that their morbidity was much increased: at 1 year the proportion not requiring hospital admission in group IV was 31%, versus 86% in group I (low TAC urea , long dialysis time), P50´0001. As well as having morbidity the high TAC urea groups had more neurotoxicity, 16 as evidenced by decreased peripheral nerve conduction, and more electroencephalographic abnormalities, higher serum potassium, hydrogen ion, 17 phosphate and parathyroid hormone concentrations 18 and lower haemoglobin. 19 Although the study was not initially designed to look at the effects of protein intake, a secondary analysis of the data showed that a low protein intake, re¯ected by a low normalized protein catabolic rate (NPCR), was a better predictor of morbidity than was TAC urea . 20 Treatment failure was excessive in both high and low TAC urea groups if the NPCR was 50´8 g/kg/day. 21
CALCULATION OF Kt/V AND NORMALIZED PROTEIN CATABOLIC RATE USING UREA KINETIC MODELLING
The parameter Kt/V is the ratio between the volume of blood cleared of urea during a dialysis session (Kt) and the distribution volume (V) of blood within the patient, both calculated from blood urea measurements as described below. As K is the dialyser urea clearance (mL/min), t is the Urea kinetic modelling ± a measure of dialysis adequacy 21
Ann Clin Biochem 2001: 38 treatment time (min) and V is the body urea distribution volume (mL), it is a dimensionless parameter. It was ®rst introduced by Gotch and Sargent to quantify the dose of haemodialysis in their`mechanistic analysis' of the NCDS data in 1985, and was later applied to peritoneal dialysis. Kt/V is now widely accepted as the best single indicator of dialytic adequacy. 22 The gold standard method for determining Kt/V in haemodialysis is by urea kinetic modelling, based on Gotch and Sargent's variable-volume single-pool model used in the NCDS study. In this model two mathematical expressions are derived to describe the fall in urea concentration during dialysis and the rise of urea concentration in the interdialysis period. The equations are expressed in terms of the dialyser clearance, residual renal function, duration of dialysis, intradialytic weight loss, urea generation (G) and the volume of distribution of urea (V). Three blood urea measurements are required, one after dialysis and then one before and one after the next dialysis session, as well as an interdialysis urine collection. The two equations are solved iteratively to derive modelled values for G and V which are used to calculate Kt/V and NPCR. A number of computer programs are available which will perform urea kinetic modelling, including UR-EAKIN 23 and di-PROTON, produced by Clinical Computing Plc (London, UK).
Assuming steady-state conditions in which the patient is neither catabolic nor anabolic, the NPCR may be calculated as outlined by Borah et al.: 24
where G is urea generation (g/L) and V is the volume of distribution of urea (L).
A number of simpli®ed formulae have been proposed to calculate Kt/V directly without the need for a complex computer program. In the above model Kt/V is determined principally by the natural logarithm of the ratio of the postdialysis blood urea concentration to the predialysis blood urea concentration (R), i.e. Kt/ V=71n R, and describes the exponential fall in urea concentration during dialysis. The best bedside estimates of Kt/V are based on this relationship, and require only two urea measurements and a calculator. A commonly used formula is that derived by Daugirdas, 25 who modi®ed the simple logarithmic relationship to take account of the contribution of urea generation and urea removal by ultra®ltration during dialysis, as follows:
pre-dialysis blood [urea] t is time on dialysis (h), UF is ultra®ltrate volume (L), and W is post-dialysis weight (kg).
Movilli 26 reviewed several simpli®ed formulae to measure Kt/V. Using the same data, he calculated Kt/V by each method and found wide variations in the results obtained. At present there is no empirical evidence to indicate that any one method produces a`best' estimate of Kt/V.
UREA ESTIMATION AFTER DIALYSIS
All methods used to calculate Kt/V in haemodialysis require the measurement of post-dialysis urea concentration. Two important factors in¯uence the accuracy of this measurement: the equilibration of urea within body compartments immediately after dialysis, and the recirculation of dialyser blood within the ®stula. Both contribute to an underestimation of the postdialysis urea concentration, an overestimation of Kt/V and continued prescription of inadequate dialysis.
The single-pool model assumes that urea equilibrates instantaneously among all body compartments, but in fact urea behaves as if it is distributed between two distinct compartments, intracellular and extracellular. 27 As urea is removed from the blood during dialysis, a concentration gradient is set up between compartments. Evidence for this comes from the ®nding of a sharp increase in extracellular urea concentration immediately after dialysis stops ± the`post-dialysis' rebound that is due to the diffusion of urea from the intracellular to the extracellular compartment. Rebound is generally complete 30 min after the end of dialysis.
This phenomenon is less important for the assessment of dialysis adequacy in long-duration low-¯ux dialysis because the two compartments have time to equilibrate. However, in high-¯ux dialysis underestimation of the post-dialysis urea concentration can result in the overestimation of Kt/V by up to 25%. 28, 29 Urea kinetic modelling using a complex, time-consuming two-compartment model to avoid this requires multiple blood tests and the solving of complex equations. These dif®culties preclude its use in routine practice; interested readers might wish to refer to Vanholder's comparison of the two methods. 28 Alternatively, the post-dialysis urea sample can be taken 30 min after the end of the dialysis session, to allow full equilibration of urea within the body, but this is unpopular with patients and has signi®cant time implications in a service already under pressure.
The accuracy of the post-dialysis measurement is also in¯uenced by blood recirculation, when blood from the dialyser venous line recirculates to the dialyser arterial line if blood ow through the ®stula is turbulent owing to venous stenosis, or if the venous and arterial needle positions are reversed. The result is a reduction in the rate of urea removal during dialysis and hence less ef®cient dialysis; it also causes a falsely low estimate of the post-dialysis urea concentration, which is measured on a sample taken from the arterial line. Various methods have been proposed for taking samples from the arterial line to limit recirculation. 30 The methods differ according to the blood¯ow rate at the time of sampling and the presence or absence of venous clamping. Agreement is required not only on the best method to calculate Kt/V, but also on the most appropriate technique for taking the post-dialysis sample.
Kt/ V IN PERITONEAL DIALYSIS
Peritoneal dialysis requires a different model. As it is a continuous treatment the serum urea and total body water remain constant. Patients more often have functioning kidneys, which also clear urea in the urine. The same equation can be used to calculate both renal and peritoneal urea clearances. A 24 h urine and dialysate collection is made and urea is measured in blood taken during or at the end of the collection period. Kt/ V is calculated for both renal and peritoneal clearance and the values are added together. 31 The volume of distribution of urea is calculated using anthropometric data by Watson's equation 32 (see below).
Kt/V=(Vol/1´44)6(CF/CB)6(1440/V) Vol is dialysate or urine volume in 24 h (mL) CF is urea concentration in dialysate or urine (mmol/L) CB is urea concentration in blood (mmol/L) V is distribution volume estimated by Watson's equation (mL)
Watson's equation:
Males: V=24477(95´166age (yr))+(107´46height (cm))+(336´26weight (kg)) mL Females: V=(106´96height (cm)) + (246´66weight (kg))72097 mL A useful adjunct to the calculation of Kt/V in peritoneal dialysis is the peritoneal equilibration test (PET). This test, devised by Twardowski et al. 33 assesses the peritoneal membrane transport characteristics in terms of solute clearance and ultra®ltration. The results are used to select the peritoneal dialysis regimen most appropriate for the permeability characteristics of the patient. It is also used to monitor patients over time, and aids diagnosis of the causes of inadequate solute clearances and ultra®ltration failure. The PET is particularly helpful in identifying the cause of ultra®ltration failure, which can be due to a number of factors, including membrane failure or high peritoneal solute transfer rates which cause early loss of an osmotic gradient and poor ultra®ltration. Unlike Kt/V the PET is of limited value for prescribing the dose of dialysis.
HOW MUCH Kt/ V IS ENOUGH?
Since the NCDS there has been a plethora of studies looking at levels of Kt/V for urea and its effect on clinical outcome. The ®rst was Gotch and Sargent's mechanistic analysis of the NCDS data. 22 They suggested that most treatment failures, de®ned as hospitalization and/or the appearance of de novo clinical abnormalities or worsening of residual morbidity in any organ system, occurred at a Kt/V50´8. They interpreted the data as showing a stepwise fall in morbidity above that level, and maintained that the probability of treatment failure did not decrease as Kt/V declined from 0´9 to 1´5. They concluded that a Kt/V of 1´0 was`fully adequate'.
Keshaviah 34 has reanalysed the NCDS data, and suggested that an exponential fall in morbidity ®ts the data better than a stepwise drop and saw bene®t up to a Kt/V of 1´6. Held et al. 35 looked at 7096 patients from the`United States renal data system' and saw an average 7% decrease in mortality for every increase in Kt/V of 0´1, up to a value of 1´3. Parker et al. 36 saw lower mortality when Kt/V was increased from 1´2 to 1´4. Lastly, Charra's unit in Tassin, France, 37 has the world's best survival ®gures, and although patient selection, as well as optimal blood pressure control, plays a part, they obtain 87% 5-year and 43% 20-year survival rates with Kt/V values between 1´6 and 1´9. Comparisons between studies should be made with caution, taking account of the method used to calculate Kt/V. Do we have enough information to say what the optimum dialysis prescription should be? Kjellstrand 38 took the data from Parker, Keshaviah and Charra and extrapolated the logarithmic morbidity versus Kt/V line (see Fig.  1 ) suggested by Keshaviah. 34 He hypothesized that there may still be additional bene®ts in morbidity/mortality up to a Kt/V of 3´0. This is equivalent to native renal urea clearance of 30 mL/min and would require thrice-weekly dialysis of at least 7 h, with high-¯ux dialysers capable of achieving clearances of 300 mL/min. A dialysis membrane is not a real kidney. It does not have tubules to change the composition of the dialysate, nor active transport mechanisms to reclaim useful molecules which are ®ltered. High-¯ux dialysis has been shown to lead to excessive losses of water-soluble vitamins such as B 6 39,40 and folate, and it is easy to envisage a situation in which morbidity and mortality begin to rise as we approach these very high urea clearances. We therefore need trial evidence to prove that even higher Kt/V levels are bene®cial.
THE CANADA±USA PERITONEAL DIALYSIS (CANUSA) STUDY
Although the quantity of dialysis was shown to affect outcome in haemodialysis as early as 1981, 15 it was not until the Canada±USA Peritoneal Dialysis (CANUSA) study in 1996 41 that this was shown de®nitively for continuous ambulatory peritoneal dialysis (CAPD). Previous trials 43±45 had shown con¯icting results concerning the correlation between Kt/V and patient survival. These studies suffered from the lack of patient numbers inherent in single-centre studies and the high rate of technique failure with CAPD; only 20% of patients completed 30 months of Blake's study. 42 The CANUSA trial recruited 680 patients from 14 centres, with follow-up of at least 3 years. The effects of dialytic adequacy and nutrition on survival were assessed every 6 months. Dialytic adequacy was measured by weekly creatinine clearance, normalized to body surface area, and Kt/V for urea in both the dialysate and urine. Estimates of nutritional status included serum albumin concentration, NPCR, percentage lean body mass, which was determined from creatinine kinetics, 46 and a subjective global assessment of nutritional status. This has been shown to be a valid indicator of nutrition in CAPD. 47 It involves subjective scoring of four items: anorexia, weight loss during the preceding 6 months, subcutaneous fat and muscle mass. The lower the score, the worse the nutritional status.
Relative risk of death was assessed according to Cox's proportional hazards model 48 and was found to increase with indicators of poor nutrition and underdialysis, as well as with increased age, insulin-dependent diabetes and cardiovascular disease. For every one-unit decrease in the`subjective global assessment' there was a 25% increase in mortality risk. There was a 6% increase in mortality risk for each 1 g/L drop in serum albumin and a 3% increase in risk for each 1% drop in lean body mass. NPCR did not correlate with outcome. It has been suggested that NPCR is not a good marker of nutrition in CAPD because it is normalized to standard body weight, rather than ideal body weight. 49 Both creatinine clearance and Kt/V were useful in predicting mortality risk. For each extra 5 L/week/1´73 m 2 increase in creatinine clearance the relative risk of death decreased by 7%. Likewise, for each increase in Kt/V of 0´1 the relative risk decreased by 6%. In CAPD a weekly Kt/V of 2´1 or creatinine clearance of 70 L/week/1´73 m 2 was associated with an expected 2-year survival of 78%. It is interesting to compare the levels of urea clearance needed for adequate dialysis between the two modalities. CANUSA suggests that a weekly Kt/V of 2´1 is adequate for CAPD, whereas NCDS and the other haemodialysis studies discussed above consider a weekly Kt/V of 3´0 to be a bare minimum, with bene®t possibly seen up to 5´7. Keshaviah 50 has considered this problem and presents data to suggest that this is not due to the improved large-molecule clearance with CAPD, but that it is explained by his peak concentration hypothesis. This states that the higher morbidity in haemodialysis is related to the high concentrations of toxins in the interdialytic period, rather than the relative removal of toxins. As CAPD is continuous it does not have high peaks, and patients do better with lower clearances. This has obvious connotations in extrapolating the adequacy data from CANUSA to the nocturnal intermittent peritoneal dialysis which is becoming more popular in younger patients who work during the day.
NUTRITION
The prevalence of protein±energy malnutrition is high in patients treated with haemodialysis and peritoneal dialysis. 51 In both the NCDS and the CANUSA studies nutrition proved to be as important as the quantity of dialysis in determining outcome. 20, 52 It has been suggested that this is due at least in part to mathematical coupling of PCR and Kt/V. 53, 54 This is refuted by the CANUSA trial, 52 in which subjective global assessments of nutrition and serum albumin level (which are not mathematically related) were both higher in those patients who achieved higher Kt/V or creatinine clearance. Lowrie and Lew 55 showed that low serum albumin, cholesterol and creatinine, all of which may be considered markers of poor nutrition, were the best predictors of poor outcome in dialysis patients.
Inadequate dialysis is commonly associated with loss of appetite and spontaneous reduction in protein and energy intake. Intensive dietary counselling is not enough to increase a patient's protein intake. 56, 57 Lindsay showed in haemodialysis patients that increasing the quantity of dialysis resulted in an increase in dietary protein intake and PCR. 58±60 Dialysis dose has also been shown to in¯uence protein intake in patients on CAPD. 58 Good-quality dialysis is thus required in order to attain satisfactory nutritional status. Nutrition assessment is therefore a fundamental part of the measurement of dialytic adequacy.
CONCLUSIONS
Both quantity of dialysis and adequate protein nutrition have been shown to be important factors in¯uencing outcome in dialysis patients. Urea kinetic modelling is a useful tool for monitoring dialysis, as it provides important information regarding both small-molecule clearance as Kt/V and protein intake as NPCR. There are various methods to calculate these indices but no consensus as to which one should be used.
There has been a gradual increase in the recommended minimum Kt/V since Gotch and Sargent 22 stated that no bene®t is to be gained by increasing it above 1´0. Improved urea clearance results in higher protein intake and almost certainly in improved survival. The maximum urea clearance which is bene®cial has not yet been clearly established. Kt/V is now measured in all dialysis units in the UK, and the Renal Association±Royal College of Physicians standards document 61 suggests a minimum stable Kt/ V of 41´2 for thrice-weekly haemodialysis, and a weekly Kt/V of 1´7 for CAPD.
Kjellstrand 38 compared dialysis in the USA with that of Charra's group in France. Because of the shorter dialysis time and lower Kt/V values achieved in the USA, individual patients' relative risk of dying is four times higher. However, US centres accept three times the proportion of potential patients on to their dialysis programmes, and this leads to 2´7 times as many patient life-years being saved in the USA as in France. It is clear that we must judge what is best for the individual patient and for the dialysis population as a whole. Perhaps the greatest challenge is to decide how to use the measure of Kt/V for the bene®t of dialysis patients, rather than have it used as a stick to press for conformity of treatment and to limit costs.
